Written by Klarity Editorial Team
Published: Jul 15, 2026

Last updated: July 15, 2026
2026 Key Update — Cigna/ESI Zepbound Status: Unlike some competitors, Cigna’s pharmacy benefit manager, Express Scripts (ESI), did not remove Zepbound (tirzepatide) from its commercial formulary. Zepbound remains available at Tier 3–4 with prior authorization for eligible Cigna members — an important distinction for West Virginia residents comparing weight loss coverage options. See if Klarity’s licensed WV providers may be able to help you start treatment →
If you have Cigna health insurance in West Virginia and are exploring weight loss treatment options, understanding what your plan may cover — and what steps are required — can make the difference between starting treatment and facing unexpected out-of-pocket costs. This guide covers Cigna’s 2026 weight loss formulary through Express Scripts (ESI), prior authorization requirements under West Virginia Senate Bill 267, the Electronic Prescribing for Controlled Substances (EPCS) rules that apply to certain weight loss medications, and how to verify your specific benefits before booking an appointment.
Cigna offers several commercial plan types in West Virginia for 2026. The type of plan you have affects your network access, referral requirements, and cost-sharing structure:
Note: Cigna also administers many self-funded employer plans in West Virginia. Self-funded plans may have different formulary structures, prior authorization rules, and cost-sharing than the standard commercial plans listed above. Always verify benefits through your member portal at myCigna.com or by calling Cigna member services at 1-800-244-6224.
Cigna administers its pharmacy benefits through Express Scripts (ESI). The following table reflects the typical ESI commercial formulary tier placement and prior authorization requirements for common weight loss medications in 2026. Actual coverage depends on your specific plan design — verify with your plan documents or Cigna member services.
| Medication | Drug Class | ESI Tier (Typical) | Prior Authorization | Notes |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 agonist | Tier 3–4 | Yes — BMI + comorbidity criteria | Non-scheduled; EPCS inapplicable |
| Zepbound (tirzepatide) | GLP-1/GIP dual agonist | Tier 3–4 | Yes — BMI + comorbidity criteria | NOT removed from ESI formulary — key differentiator vs. CVS/Caremark |
| Saxenda (liraglutide) | GLP-1 agonist | Tier 3–4 | Yes — PA required | Non-scheduled; EPCS inapplicable |
| Contrave (naltrexone/bupropion) | Opioid antagonist/NDRI | Tier 2–3 | PA likely — verify with plan | Non-scheduled; EPCS inapplicable |
| Qsymia (phentermine/topiramate ER) | Stimulant combination | Tier 2–3 | Yes — PA + REMS enrollment | Schedule IV; EPCS applies in WV under § 60A-4-403a; REMS certification required |
| Phentermine (generic) | Sympathomimetic stimulant | Tier 1–2 | Typically no PA — quantity limits apply | Schedule IV; EPCS applies in WV under § 60A-4-403a; short-term use only |
| Orlistat (generic) | Lipase inhibitor | Tier 1–2 | Typically no PA | Non-scheduled; EPCS inapplicable |
| Alli (orlistat OTC) | Lipase inhibitor (OTC) | Not covered | N/A | OTC drugs generally not covered under prescription benefit |
| Mounjaro (tirzepatide) | GLP-1/GIP dual agonist | Tier 3–4 | Yes — for T2D indication only | FDA-approved for Type 2 diabetes, not weight loss; covered for diabetes indication |
| Ozempic / Rybelsus (semaglutide) | GLP-1 agonist | Tier 3–4 | Yes — for T2D indication only | FDA-approved for Type 2 diabetes; Ozempic off-label weight loss typically not covered |
Disclaimer: Formulary placement, tier assignments, and PA requirements may vary by plan type, employer group, and plan year. Always verify your specific benefits at myCigna.com or by calling 1-800-244-6224 before filling a prescription.
One of the most clinically significant formulary developments of 2025–2026 was CVS/Caremark’s decision to remove Zepbound from its commercial formularies — a decision that affected members on Aetna and other CVS/Caremark-administered plans. CVS/Caremark subsequently reinstated Zepbound effective October 1, 2026, following significant member and provider advocacy.
Cigna/ESI did not remove Zepbound. Throughout this period, Zepbound remained on the ESI commercial formulary at Tier 3–4 with standard prior authorization requirements. For West Virginia Cigna members considering tirzepatide for weight loss, this means that coverage continuity was maintained — no formulary gap or forced transition to an alternative medication occurred.
This distinction is worth noting when comparing plans or when speaking with a provider about GLP-1 coverage options. If your employer offers a choice between Cigna/ESI and an Aetna/CVS Caremark plan, the formulary stability of Zepbound on ESI may be a relevant factor in your benefits decision.
West Virginia’s controlled substance prescribing law, W. Va. Code § 60A-4-403a, requires electronic prescribing for all controlled substances — not just Schedule II as in most states. This is a WV-specific nuance that affects which weight loss medications require an electronic prescription.
For weight loss medications specifically:
For most Cigna WV members pursuing weight loss treatment, the EPCS requirement is effectively handled by the prescriber. However, verifying that your provider is EPCS-compliant (and REMS-certified if prescribing Qsymia) is a practical step that can prevent prescription delays.
West Virginia Senate Bill 267 (2024) established electronic-only prior authorization submission requirements for commercial insurers operating in West Virginia. Under SB 267:
Typical prior authorization criteria for weight loss medications on Cigna/ESI commercial plans in 2026 may include:
PA timelines under Cigna commercial plans typically follow these windows:
W. Va. Code § 33-25-8r et seq. is West Virginia’s mental health and substance use disorder parity statute. This law requires commercial insurers to apply the same coverage limitations to mental health and SUD benefits as they apply to comparable medical/surgical benefits.
This statute does not govern weight loss treatment coverage. Weight loss is not classified as a mental health or substance use disorder condition under MHPAEA or the WV parity statute. The coverage frameworks that govern weight loss medication coverage for Cigna WV members are:
If you believe your Cigna plan is wrongly denying weight loss medication coverage, you may have appeal rights under ERISA or through the WV Insurance Commissioner. Contact information is listed below.
Effective July 1, 2026, CMS launched a Medicare GLP-1 Bridge program providing eligible Medicare Advantage members access to Wegovy, Zepbound, and Foundayo at $50/month. This program applies to Medicare Advantage plans only — it does not apply to Cigna commercial plans, self-funded employer plans, or ACA Marketplace plans. If you have Cigna commercial coverage (through an employer or the Marketplace), the Medicare GLP-1 Bridge program is not relevant to your benefits.
Before scheduling a weight loss consultation, the following five-step verification process may help you understand your specific benefits and avoid unexpected costs:
Klarity Health connects West Virginia residents with a network of 2,000+ licensed providers who offer telehealth weight loss consultations. Klarity providers are familiar with Cigna’s PA requirements, EPCS compliance mandates under West Virginia law, and the practical steps for getting weight loss medications covered.
When you book through Klarity, your provider can:
Coverage for weight loss treatment varies by Cigna plan. Klarity recommends verifying your specific benefits before your first appointment. Learn more about weight loss treatment options at Klarity →
Zepbound (tirzepatide) typically remains on the Cigna/ESI commercial formulary at Tier 3–4 with prior authorization. Unlike CVS/Caremark (Aetna’s PBM), Express Scripts did not remove Zepbound from its commercial formulary. Coverage requires meeting PA criteria — typically BMI ≥ 30, or BMI ≥ 27 with a qualifying comorbidity — and your provider must submit a PA request via Availity under WV SB 267. Verify your specific plan’s current formulary at myCigna.com.
Wegovy (semaglutide) may be covered under Cigna commercial plans through the ESI formulary at Tier 3–4, subject to prior authorization. PA criteria typically include BMI ≥ 30 or BMI ≥ 27 with a comorbidity, plus documentation of a prior structured weight management attempt. Coverage and cost-sharing depend on your specific plan design — confirm through myCigna.com or by calling 1-800-244-6224.
Referral requirements depend on your plan type. OAP (Open Access Plus) plans typically do not require a referral to see a weight loss medicine specialist. HMO plans typically require a referral from your PCP. LocalPlus/SureFit plans do not require a referral but restrict you to an in-network provider list. Check your plan documents or myCigna.com to confirm your plan’s specific referral rules.
Yes. Phentermine is a Schedule IV controlled substance. Under W. Va. Code § 60A-4-403a, West Virginia requires electronic prescribing for all controlled substances — including Schedule IV. Your provider must be EPCS-compliant to prescribe phentermine in West Virginia. GLP-1 medications (Wegovy, Zepbound, Saxenda) are non-controlled and do not have this requirement.
No. W. Va. Code § 33-25-8r et seq. is West Virginia’s mental health and substance use disorder parity statute — it governs parity for mental health and SUD benefits, not weight loss. Weight loss medication coverage is governed by ACA essential health benefits rules (for Marketplace plans) and employer plan design (for employer-sponsored plans). ERISA self-funded plans are not bound by West Virginia state coverage mandates. Contact the WV Insurance Commissioner at 1-888-879-9842 if you believe a coverage denial was improper.
If Cigna denies your PA request, you typically have the following options: (1) Request a peer-to-peer review — your prescribing provider speaks directly with Cigna’s medical reviewer to discuss clinical necessity. (2) File a first-level internal appeal within the timeframe stated on your denial letter (typically 30–60 days). (3) If the first appeal is denied, request an external independent review through the WV Insurance Commissioner’s office (1-888-879-9842). For ERISA self-funded plans, contact the U.S. Department of Labor EBSA at 1-866-444-3272. Document all communications and keep copies of your PA submission materials.
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, insurance advice, or a guarantee of coverage. Coverage for weight loss treatment varies significantly by Cigna plan type, employer group, and plan year. Always verify your specific benefits through myCigna.com or by calling Cigna member services at 1-800-244-6224 before scheduling treatment or filling a prescription. Klarity Health is not affiliated with Cigna or Express Scripts.
Find the right provider for your needs — select your state to find expert care near you.